Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Worksport Ltd. has signed a term sheet for its first-ever acquisition, targeting a patented, U.S.-manufactured truck bed accessory business and its IP portfolio. The company plans to leverage its existing West Seneca manufacturing facility and distribution network to cross-sell and bundle the new product with its tonneau covers.
MoonLake Immunotherapeutics reported Q3 2026 financial results and announced the submission of a Biologics License Application (BLA) to the FDA for sonelokimab in hidradenitis suppurativa. The company ended the quarter with $498.5 million in cash and equivalents, providing a projected cash runway into mid-2028.
CDW Corporation reported third quarter 2026 financial results with net sales of $6.75 billion, a 17.7% increase year-over-year, driven by strong enterprise AI adoption and broad-based customer demand. The company also declared a quarterly cash dividend of $0.680 per share, payable on December 10, 2026.
“CDW delivered robust third quarter results, powered by broad-based strength across our diverse customer end-markets and strong momentum in enterprise AI adoption.”
Christine A. Leahy, chair and chief executive officer, CDW
“Strong customer demand and disciplined execution drove double-digit growth in gross profit, while operating leverage and capital management contributed to more than 20 percent growth in non-GAAP net income per diluted share.”
Nuvectis Pharma reported third quarter 2026 financial results and provided a corporate update following its transformational in-licensing of ex-China rights to NXP100 and NXP200. The company ended the quarter with approximately $140 million in cash, providing a projected runway into the second half of 2029. Management is currently in discussions with the FDA regarding the U.S. regulatory path for ciprocopan (NXP100) in PNH and expects to provide an update by year-end.
“The last few months have been truly transformational for Nuvectis. The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
RYTHM, Inc. reported third quarter 2026 revenue of $23.9 million, a 4% sequential increase, and a net loss of $0.5 million. The company highlighted significant growth in its THC beverage portfolio, reaching an annualized run rate of 320,000 cases and expanding retail availability to 8,000 doors across 18 states.
CPI Card Group reported net income of $5.0 million for the third quarter of 2026, more than doubling the $2.3 million reported in the prior year period, driven by a 14.8% increase in revenue to $158.4 million. The company implemented a new segment structure in 2026, separating its proprietary technological solutions into a new Integrated Paytech segment following the acquisition of an on-premise instant issuance solution.
Criteo S.A. reported third quarter 2026 financial results with revenue of $416 million and net income of $6 million. The company highlighted the expansion of its Performance Connected TV capabilities into global markets and its ongoing advertising technology partnership with OpenAI.
“Despite near-term headwinds, we are making tangible progress across our business, with momentum in newer channels and a growing pipeline of opportunities. As we sharpen execution and operate with greater discipline, we remain focused on capturing the opportunities ahead and creating sustainable value for our shareholders.”
Michael Komasinski, Chief Executive Officer of Criteo
Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.
Term
Q3 2026
“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
For the nine months ended September 30, 2026, Brink's reported revenues of $4,142.0 million, a 6.7% increase over the prior year, though net income attributable to the company decreased from $131.6 million to $91.0 million. The company experienced higher operating costs and a significant $62.4 million cash derecognition following the deconsolidation of its Malaysia business.
Charles River Laboratories International Financial Results
Charles River Laboratories reported Q3 2026 revenue of $982.7 million and organic revenue growth of 4.7%, marking its second consecutive quarter of organic growth. The company increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by outperformance in its Discovery and Safety Assessment (DSA) segment.
Term
Q3 2026
“Our third-quarter results were highlighted by a return to organic revenue growth for the second consecutive quarter and significant margin expansion, which drove non-GAAP earnings per share growth of 27%. We were pleased with the performance of our DSA and Manufacturing segments, which both delivered organic revenue growth and improved profitability.”
James C. Foster, Chairman, President and Chief Executive Officer
Wayfair reported third quarter 2026 net revenue of $3.4 billion, a 9.7% increase year-over-year, driven by 11.4% growth in its U.S. business. The company achieved net income of $62 million and grew its active customer base by 4.7% to 22.2 million, signaling structural market share gains in a flat category.
Term
Q3 2026
“Q3 was our strongest quarter of growth in the post-pandemic period, with total net revenue up 9.7% year-over-year and our U.S. business growing over 11%. That growth flowed through nicely to the bottom line, with an Adjusted EBITDA Margin of 6.9%, our best Q3 result since 2020.”
Niraj Shah, CEO, co-founder and co-chairman, Wayfair
“At the start of this year, we told you we expected to take share in the U.S. at a pace we had not seen in several years. With U.S. revenue growing double digits against a roughly flat category here in Q3, we've done exactly that. That growth was driven by orders, which were up 12% year-over-year, and active customers up more than 4%. The momentum we have on orders and customers give us confidence that our share gains are structural, and we are still in the early innings.”
Niraj Shah, CEO, co-founder and co-chairman, Wayfair
Trimble Inc. reported third quarter 2026 revenue of $966.8 million, up 7% year-over-year, and record annualized recurring revenue (ARR) of $2.56 billion. The company exceeded expectations for the quarter and updated its full-year 2026 guidance, reflecting solid execution of its Connect & Scale strategy.
Term
Q3 2026
“Our third quarter results surpassed expectations on both revenue and earnings per share, while delivering record annualized recurring revenue of $2.56 billion. Our full year 2026 guidance reflects solid execution against our Connect & Scale strategy, which continues to leverage our unique presence across the physical and digital worlds with our unmatched breadth and depth of connected industry data.”
SolarEdge Technologies reported Q3 2026 revenue of $326.1 million, meeting the midpoint of its guidance despite a 4.1% year-over-year decline. The company achieved its fifth consecutive quarter of positive free cash flow at $7.8 million and is implementing cost-reduction measures to address softer demand and reduced Q4 expectations.
Term
Q3 2026
“The SolarEdge team delivered third-quarter revenue of $326.1 million, at the midpoint of our guidance, with profitability in line with expectations. As near-term market uncertainty persists and given reduced revenue expectations for the fourth quarter, we are taking decisive steps to reduce costs, sharpen our focus, and support profitability amid softer demand.”
Q32 Bio reported third quarter 2026 financial results and provided a corporate update, including clinical data from its SIGNAL-AA trial of bempikibart. The company ended the quarter with $289.6 million in cash, which is expected to fund operations through Phase 3 topline results. Management plans to initiate a registration-directed program for bempikibart in severe alopecia areata in the first half of 2027.
Term
Q3 2026
“The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing”
Jodie Morrison, Chief Executive Officer of Q32 Bio
“We believe our data demonstrates the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata. We are pleased to welcome José and Ellie to lead the advancement of bempikibart into late-stage development and have made key senior appointments spanning clinical operations, clinical strategy and medical affairs, and regulatory affairs.”
Jodie Morrison, Chief Executive Officer of Q32 Bio
Option Care Health reported net revenue of $1.49 billion for the third quarter of 2026, a 4.1% increase over the prior year, with net income rising to $57.4 million. The company significantly improved its operating cash flow to $286.2 million for the first nine months of 2026, while continuing to execute its share repurchase program, spending $170.5 million on treasury stock.
The New York Times Company reported third-quarter 2026 results, highlighted by a 14.6% increase in digital-only subscription revenues and the addition of 420,000 net digital-only subscribers. Total revenues rose 9.7% to $768.5 million, while adjusted operating profit grew 13.9% to $149.6 million, reflecting strong marketer demand and subscriber retention.
Term
Q3 2026
“Q3 was another quarter of strong execution and sustained momentum across The Times. Our results highlighted the enduring advantages of our strategy and our multi-revenue stream model. Subscriber growth was powered by strong engagement and retention across our portfolio. We grew operating profit and generated healthy free cash flow while continuing to invest in growth areas like video. As the information ecosystem continues to evolve, our essential subscription strategy — which is about human-made journalism and product experiences that people seek out directly and make room for in their lives — provides powerful advantages that we believe will only deepen with time.”
Meredith Kopit Levien, president and chief executive officer, The New York Times Company
BioCryst reported Q3 2026 total net revenue of $180.3 million, driven by $174.8 million in ORLADEYO sales, and achieved an operating profit of $53.3 million. The company increased its full-year total revenue guidance to $715-$730 million and highlighted the recent FDA approval of ORLADEYO oral pellets for patients aged 12 and older.
Term
3 years
“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success.”
Charlie Gayer, President and Chief Executive Officer
“This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders.”
Charlie Gayer, President and Chief Executive Officer
SharkNinja reported third quarter 2026 net sales of $1.98 billion, a 21.2% increase year-over-year, driven by strong performance in Cooking and Beverage Appliances and International markets. Net income rose 79.3% to $338.4 million, and the company raised its full-year 2026 outlook based on strong operational performance and innovation across its product categories.
Term
Q3 2026
“Q3 net sales grew 21.2%, marking our second consecutive quarter above 20% and our 14th consecutive quarter of double-digit growth. Our topline strength was well balanced across Domestic and International, with tremendous performance across channels, categories, and geographies. We believe this reflects our evolution into a Consumer Technology company operating at hyperscale, which shows up in what we make, how we market and sell, how fast we learn, and how far we reach.”
The Brink's Company reported third-quarter 2026 results with revenue of $1.375 billion, up 3% year-over-year, driven by strong organic growth in ATM Managed Services (AMS) and Digital Retail Solutions (DRS). The company also provided an update on its pending acquisition of NCR Atleos, which is now expected to close in early January 2027 following regulatory progress in the UK.
“We delivered a strong third quarter and continued to build real momentum in our strategic focus areas of AMS and DRS. Growth in these lines of business accelerated sequentially, even against a challenging economic backdrop in many of our larger markets. Adjusted EBITDA grew 8%, and margins expanded by 90 basis points year-over-year, powered by favorable revenue mix and strong pricing dynamics.”
Mark Eubanks, President and CEO
“We are making strong progress toward closing our acquisition of NCR Atleos. With increasing clarity and momentum on the regulatory front, including the recent developments with the CMA in the United Kingdom, we now expect to close the acquisition in early January 2027.”
The Kraft Heinz Company appointed Kelly M. Dilts and J. Michael Schlotman to its Board of Directors, effective November 4, 2026. Ms. Dilts currently serves as CFO of Nordstrom, and Mr. Schlotman is the former CFO of The Kroger Co. The appointments add deep retail, grocery, and financial expertise to the board as the company continues its transformation strategy.
Cushman & Wakefield reported third quarter 2026 revenue of $2.81 billion, an 8% increase year-over-year, driven by strong growth in leasing and capital markets. Adjusted EPS rose 28% to $0.37, while the company reaffirmed its full-year 2026 adjusted EPS growth guidance of 18% to 23%.
Term
Q3 2026
“Today we reported our seventh consecutive quarter of double-digit adjusted earnings per share growth, showcasing the power of our balanced platform and strategy. With $800 million in debt paydowns since 2024 our balance sheet has been transformed, and we enter this next stage of growth with increased strength, stability and optionality.”
Michelle MacKay, Chief Executive Officer of Cushman & Wakefield
“In three years, we have built a more agile and future-ready company, and the opportunity in front of us has never been greater. Our teams have consistently delivered, and we will continue to focus on converting the strength we have built into durable, profitable long-term growth.”
Michelle MacKay, Chief Executive Officer of Cushman & Wakefield
Marriott Vacations Worldwide reported Q3 2026 financial results with contract sales increasing 29% year-over-year to $565 million and Adjusted EBITDA growing 27% to $216 million. The company raised its full-year guidance for contract sales and Adjusted EBITDA despite an estimated $16 million negative impact from Hurricane Lowell.
Term
Q3 2026
“We are very pleased with our third quarter financial results, as they demonstrate the substantive momentum in our business, on the heels of our strong second quarter. Further, they reflect the continued success of the strategies we began implementing in the second quarter as part of the transformation now underway. By way of example, VPG increased to an industry leading $4,822, 30% above last year, and our operating discipline drove 27% Adjusted EBITDA growth.”
Genprex announced new research identifying TROP2 expression as a potential predictive biomarker for response to its lead gene therapy candidate, Reqorsa, in non-small cell lung cancer (NSCLC). Data from preclinical models and patient biopsies showed that low TROP2 expression is associated with resistance to treatment, which could help the company select more applicable patients for future clinical trials.
McDonald's Corporation reported third quarter 2026 financial results with global systemwide sales increasing 4% to over $38 billion. While U.S. comparable sales declined slightly by 0.2%, consolidated operating income grew 7% and diluted earnings per share rose 10% to $3.51.
Term
Q3 2026
“McDonald’s delivered another quarter of global growth, with solid performance across much of our international business. In the U.S., we're encouraged by improvement as the quarter progressed following our intervention on value. We’re focused on building from here, strengthening the business today and investing in the next chapter of growth.”
D-Wave Quantum announced performance enhancements to its Stride hybrid solver and launched a new three-course Applied Quantum Optimization learning path. The updated solver, available via the Leap quantum cloud service, demonstrated significant speed and quality improvements in benchmark testing for complex optimization problems like the traveling salesperson problem.
Insulet reported Q3 2026 revenue of $842 million, a 19.2% increase year-over-year, driven by strong Omnipod sales in both U.S. and international markets. Alongside the earnings, the company announced a new $1 billion stock repurchase program authorized through 2028, with $400 million planned for the fourth quarter of 2026.
Martin Marietta reported record third-quarter 2026 revenues of $2.37 billion, a 28% increase driven by the acquisition of Lhoist North America (LNA). While net earnings from continuing operations decreased 29% to $256 million due to inflationary pressures and acquisition-related costs, Adjusted EBITDA rose 21% to $808 million.
“Martin Marietta delivered record quarterly revenues of $2.37 billion and Adjusted EBITDA from continuing operations of $808 million, representing increases of 28% and 21%, respectively, over the prior year third quarter, as strong performance from recent acquisitions more than offset the effects of expanding inflationary pressures and a dynamic macroeconomic environment.”
Kraft Heinz reported third-quarter 2026 results with net sales of $6.1 billion, a 2.0% decrease compared to the prior year. The company updated its full-year outlook, raising the low end of its Organic Net Sales guidance while reporting a 14.6% decrease in operating income to $0.9 billion.
Term
Q3 2026
“Our 2026 operating plan to turn around the U.S. business and accelerate growth internationally is on track. Relative to last year, our market share, sales, and volume trends are improving in every region. We are increasingly meeting consumers where they are, and giving them more reasons to choose our brands.”
Steve Cahillane, CEO of Kraft Heinz
“As we approach the end of the year, we are raising the low end of our Organic Net Sales outlook, reflecting the momentum we have built. That progress is supported by a strong balance sheet, which gives us the flexibility to keep investing in our brands and our people.”
CPI Card Group reported record third quarter 2026 revenue of $158 million, a 15% increase year-over-year, driven by double-digit growth across all business segments. Net income rose 117% to $5 million, and the company raised its full-year 2026 guidance for revenue growth and free cash flow for the second consecutive quarter.
Term
Q3 2026
“The third quarter marked another quarter of strong revenue, Adjusted EBITDA and Free Cash Flow growth, while we continued to invest in the business to help our customers win. Double-digit growth across each of our segments, improved profitability and strong commercial wins demonstrate the progress we are making against our strategy. We are gaining share while executing on our growth strategy to expand our capabilities, diversify our business and create new avenues for long-term growth and shareholder value creation.”
Smith Douglas Homes reported third quarter 2026 results with home closing revenue of $262.5 million and diluted EPS of $0.07. While home closings and net new orders increased, profitability was impacted by higher mortgage rates and affordability pressures, leading to a decrease in pretax income to $3.3 million compared to $17.2 million in the prior year period.
Term
Q3 2026
“We continued to execute with discipline during the third quarter despite increasingly challenging housing market conditions. Higher mortgage rates and affordability pressures have weighed on buyer demand and profitability, but our teams remain focused on things we can control with respect to managing costs, building efficiently, and maintaining a steady absorption pace.”
Greg Bennett, Chief Executive Officer and Vice Chairman
“Our land-light operating model, efficient construction cycle times, and conservative balance sheet provide us with the flexibility to manage through periods of weaker demand without compromising our long-term objectives.”
Russ Devendorf, Executive Vice President and Chief Financial Officer